Skip to main content

Advertisement

Table 1 Patients' characteristics

From: Economic burden of beta-thalassemia/Hb E and beta-thalassemia major in Thai children

  Hospital
  Saraburi Phramongkutklao Chulalongkorn Total
Number 72 (35.8%) 42 (20.9%) 87 (43.3%) 201 (100%)
Age; mean years (SD) 9.24 (3.89) 11.38 (3.84) 8.86 (3.48) 9.52 (3.82)
Gender (N = 201)     
   Male 34 (47.2%) 24 (57.1%) 49 (56.3%) 107 (53.2%)
   Female 38 (52.8%) 18 (42.9%) 38 (43.7%) 94 (46.8%)
Type of payment (N = 201)     
   Universal Coverage Scheme (UC) 66 (91.7%) 24 (57.1%) 33 (37.9%) 123 (61.2%)
   Civil Servant Medical Benefit Scheme (CSMBS) 1 (1.4%) 12 (28.6%) 11 (12.6%) 24 (11.9%)
   Out of pocket 5 (6.9%) 6 (14.3%) 43 (49.4%) 54 (26.9%)
Disease type (N = 201)     
   Beta-thal/Hb E 68 (94.4%) 37 (88.1%) 78 (89.7%) 183 (91.0%)
   Homozygous beta-thalassemia 4 (5.6%) 5 (11.9%) 9 (10.3%) 18 (9.0%)
Severity (N = 200)     
   Severe 38 (52.8%) 14 (34.1%) 42 (48.3%) 94 (47.0%)
   Non-severe 34 (47.2%) 27 (65.9%) 45 (51.7%) 106 (53.0%)
Splenectomy* (N = 201)     
   Yes 22 (30.6%) 19 (45.2%) 22 (25.3%) 63 (31.3%)
   No 50 (69.4%) 23 (54.8%) 65 (74.7%) 138 (68.7%)
Type of blood transfusion (N = 198)     
   No 23 (31.9%) 8 (19.0%) 10 (11.9%) 41 (20.7%)
   Occasional (1-5 times/year) 24 (33.3%) 1 (2.4%) 15 (17.9%) 40 (20.2%)
   Low (6-12 times/year) 24 (33.3%) 22 (52.4%) 33 (39.3%) 79 (39.9%)
   High (> 12 times/year) 1 (1.4%) 11 (26.2%) 26 (31.0%) 38 (19.2%)
Iron chelation (N = 201)     
   Desferrioxamine 3 (4.2%) 27 (64.3%) 48 (55.2%) 78 (38.8%)
   No drug 69 (95.8%) 15(35.7%) 39 (44.8%) 123 (61.2%)
Ferritin level (N = 127)     
   ≤ 2,500 ng/ml 16 (80.0%) 20 (58.8%) 41 (56.2%) 77 (60.6%)
   > 2,500 ng/ml 4 (20.0%) 14 (41.2%) 32 (43.8%) 50 (39.4%)
Complications (N = 201)     
   Yes 5 (6.9%) 13 (31.0%) - 18 (9.0%)
   No 67 (93.1%) 29 (69.0%) 87 (100.0%) 183 (91.0%)
  1. * prevalence